BASF starts up production plant for specialty amines in Ludwigshafen
![](/46/pdcnewsitem/03/78/34/BASF.png)
Global leadership position in specialty amines strengthened.
BASF in Ludwigshafen has started up a world-scale plant for the production of specialty amines. The multi-product plant can manufacture approximately 12,000 metric tons per year of a product range of about 15 amines for different applications. Owing to its high flexibility, the plant can also be used for the production of new specialty amines. The major applications are currently in the construction, automotive, crop protection and pharmaceutical industries. With the new facility, BASF expands its global production network for amines with plants in Ludwigshafen and Schwarzheide in Germany; Antwerp, Belgium; Geismar, North America; and Nanjing, China.
“With the new plant, we are responding to our customers’ growing demand for specialty amines, particularly in Europe,” said Dr Stefan Blank, President, BASF Intermediates division. “We have decades of experience in developing and manufacturing amines and with the current expansion we are extending our global leadership in these versatile intermediates.”
“The special plant structure allows us to react flexibly to changes in the need for the various products. In addition, we can also produce commercial quantities of products from our innovation pipeline here,” said Dr Christoph Wegner, Senior Vice President, heading the regional business unit Amines Europe within BASF’s Intermediates division, and adds: “Being integrated into the BASF Verbund at the Ludwigshafen site also allows us to offer our customers, apart from research, the scale-up services through a pilot plant, all the way to the new multi-product plant.”
With about 200 different amines, BASF has the world’s most diverse portfolio of these chemical intermediates. In addition to alkylamines, alkanolamines and alkoxyalkylamines, the company also offers heterocyclic and aromatic amines as well as specialty amines. The range is completed by an expanding portfolio of chiral amines with high optical and chemical purity. The versatile products have proven their effectiveness above all in the manufacture of crop protection products and pharmaceuticals, as well as in cosmetics, detergents and process chemicals. They are also needed to produce coatings, special plastics, composites and special fibers.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance